Do analysts prefer EVMN or JMAC?

Evommune currently has a consensus target price of $49.25, suggesting a potential upside of 148.36%. Given Evommune's stronger consensus rating and higher probable upside, equities research analysts clearly believe Evommune is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evommune 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.00 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, EVMN or JMAC?

Maxpro Capital Acquisition has lower revenue, but higher earnings than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 54.94 -$68.87M -$9.50 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is EVMN or JMAC more profitable?

Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Maxpro Capital Acquisition N/A N/A N/A

Do analysts prefer JMAC or DRUG?

Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 135.99%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86

Which has higher earnings & valuation, JMAC or DRUG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A

Is JMAC or DRUG more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Bright Minds Biosciences N/A -20.58% -20.25%

Do analysts recommend JMAC or AVTX?

Avalo Therapeutics has a consensus target price of $46.67, suggesting a potential upside of 216.17%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85

Which has stronger earnings & valuation, JMAC or AVTX?

Maxpro Capital Acquisition has higher earnings, but lower revenue than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Avalo Therapeutics $59K 13,150.41 -$78.26M -$5.46 N/A

Is JMAC or AVTX more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Avalo Therapeutics N/A -97.54% -72.42%

Do analysts recommend SLDB or JMAC?

Solid Biosciences presently has a consensus target price of $17.00, suggesting a potential upside of 138.10%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, SLDB or JMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is SLDB or JMAC more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Maxpro Capital Acquisition N/A N/A N/A

Do analysts rate ALLO or JMAC?

Allogene Therapeutics currently has a consensus target price of $8.52, indicating a potential upside of 348.54%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, ALLO or JMAC?

Maxpro Capital Acquisition has lower revenue, but higher earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 32,789.25 -$190.89M -$0.77 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is ALLO or JMAC more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Maxpro Capital Acquisition N/A N/A N/A

Maxpro Capital Acquisition (JMAC) Competitors

$14.30 +0.61 (+4.42%)

As of 06/12/2026

Compare

JMAC vs. EVMN, DRUG, AVTX, SLDB, and ALLO

Should you buy Maxpro Capital Acquisition stock or one of its competitors? MarketBeat compares Maxpro Capital Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maxpro Capital Acquisition include Evommune (EVMN), Bright Minds Biosciences (DRUG), Avalo Therapeutics (AVTX), Solid Biosciences (SLDB), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does Maxpro Capital Acquisition compare to Evommune?

Evommune (NYSE:EVMN) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Maxpro Capital Acquisition has lower revenue, but higher earnings than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	54.94	-$68.87M	-$9.50	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Evommune had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Evommune and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 beat Evommune's score of -0.35 indicating that Maxpro Capital Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Neutral
Maxpro Capital Acquisition	Neutral

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A

Evommune currently has a consensus target price of $49.25, suggesting a potential upside of 148.36%. Given Evommune's stronger consensus rating and higher probable upside, equities research analysts clearly believe Evommune is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Evommune beats Maxpro Capital Acquisition on 6 of the 9 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Bright Minds Biosciences?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 135.99%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.53, meaning that its share price is 653% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

In the previous week, Bright Minds Biosciences had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Bright Minds Biosciences and 0 mentions for Maxpro Capital Acquisition. Bright Minds Biosciences' average media sentiment score of 1.92 beat Maxpro Capital Acquisition's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Bright Minds Biosciences	Very Positive

Maxpro Capital Acquisition's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-20.58%	-20.25%

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bright Minds Biosciences beats Maxpro Capital Acquisition on 6 of the 10 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Avalo Therapeutics?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Maxpro Capital Acquisition has higher earnings, but lower revenue than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Avalo Therapeutics	$59K	13,150.41	-$78.26M	-$5.46	N/A

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Avalo Therapeutics had 4 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 4 mentions for Avalo Therapeutics and 0 mentions for Maxpro Capital Acquisition. Avalo Therapeutics' average media sentiment score of 0.88 beat Maxpro Capital Acquisition's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Avalo Therapeutics	Positive

Maxpro Capital Acquisition's return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Avalo Therapeutics	N/A	-97.54%	-72.42%

Avalo Therapeutics has a consensus target price of $46.67, suggesting a potential upside of 216.17%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Avalo Therapeutics beats Maxpro Capital Acquisition on 8 of the 11 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Solid Biosciences presently has a consensus target price of $17.00, suggesting a potential upside of 138.10%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Solid Biosciences has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

In the previous week, Solid Biosciences had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Solid Biosciences and 0 mentions for Maxpro Capital Acquisition. Solid Biosciences' average media sentiment score of 1.09 beat Maxpro Capital Acquisition's score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Solid Biosciences	Positive
Maxpro Capital Acquisition	Neutral

Maxpro Capital Acquisition's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Maxpro Capital Acquisition	N/A	N/A	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Solid Biosciences beats Maxpro Capital Acquisition on 8 of the 11 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

In the previous week, Allogene Therapeutics had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Allogene Therapeutics and 0 mentions for Maxpro Capital Acquisition. Allogene Therapeutics' average media sentiment score of 0.69 beat Maxpro Capital Acquisition's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allogene Therapeutics	Positive
Maxpro Capital Acquisition	Neutral

Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Maxpro Capital Acquisition's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Maxpro Capital Acquisition	N/A	N/A	N/A

Allogene Therapeutics currently has a consensus target price of $8.52, indicating a potential upside of 348.54%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Maxpro Capital Acquisition has lower revenue, but higher earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,789.25	-$190.89M	-$0.77	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats Maxpro Capital Acquisition on 9 of the 12 factors compared between the two stocks.

Get Maxpro Capital Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JMAC vs. The Competition

Export

Metric	Maxpro Capital Acquisition	Holding Offices Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$192.09M	$256.17M	$4.29B	$12.05B
Dividend Yield	N/A	3.09%	10.25%	5.66%
P/E Ratio	N/A	2.32	22.29	24.42
Price / Sales	N/A	0.14	159.54	118.72
Price / Cash	N/A	127.58	40.19	37.92
Price / Book	N/A	28.95	26.92	6.82
Net Income	N/A	-$9.51M	$116.61M	$337.56M
7 Day Performance	2.18%	14.41%	0.25%	1.16%
1 Month Performance	5.18%	15.56%	0.25%	3.16%
1 Year Performance	135.55%	14.44%	14.25%	30.60%

Maxpro Capital Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JMAC Maxpro Capital Acquisition	N/A	$14.31 +4.4%	N/A	+135.6%	$192.09M	N/A	N/A	2,021
EVMN Evommune	2.3141 of 5 stars	$19.87 -4.0%	$49.25 +147.9%	N/A	$745.22M	$13M	N/A	45	Analyst Downgrade Gap Up
DRUG Bright Minds Biosciences	3.4143 of 5 stars	$69.00 -7.4%	$143.83 +108.5%	+121.0%	$725.05M	N/A	N/A	N/A	Positive News High Trading Volume
AVTX Avalo Therapeutics	3.3599 of 5 stars	$13.10 -3.7%	$48.13 +267.4%	+205.0%	$715.42M	$59K	N/A	40	Analyst Forecast Gap Down
SLDB Solid Biosciences	2.7682 of 5 stars	$6.70 -7.5%	$17.00 +153.7%	+58.3%	$712.78M	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JMAC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. EVMN, DRUG, AVTX, SLDB, and ALLO

How does Maxpro Capital Acquisition compare to Evommune?

Summary

How does Maxpro Capital Acquisition compare to Bright Minds Biosciences?

Summary

How does Maxpro Capital Acquisition compare to Avalo Therapeutics?

Summary

How does Maxpro Capital Acquisition compare to Solid Biosciences?

Summary

How does Maxpro Capital Acquisition compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. EVMN, DRUG, AVTX, SLDB, and ALLO

How does Maxpro Capital Acquisition compare to Evommune?

Which has better valuation and earnings, EVMN or JMAC?

Does the media refer more to EVMN or JMAC?

Do institutionals and insiders hold more shares of EVMN or JMAC?

Is EVMN or JMAC more profitable?

Do analysts prefer EVMN or JMAC?

Summary

How does Maxpro Capital Acquisition compare to Bright Minds Biosciences?

Do analysts prefer JMAC or DRUG?

Which has more risk & volatility, JMAC or DRUG?

Which has higher earnings & valuation, JMAC or DRUG?

Does the media refer more to JMAC or DRUG?

Is JMAC or DRUG more profitable?

Do insiders and institutionals hold more shares of JMAC or DRUG?

Summary

How does Maxpro Capital Acquisition compare to Avalo Therapeutics?

Which has stronger earnings & valuation, JMAC or AVTX?

Which has more volatility and risk, JMAC or AVTX?

Do institutionals & insiders hold more shares of JMAC or AVTX?

Does the media prefer JMAC or AVTX?

Is JMAC or AVTX more profitable?

Do analysts recommend JMAC or AVTX?

Summary

How does Maxpro Capital Acquisition compare to Solid Biosciences?

Do analysts recommend SLDB or JMAC?

Which has more volatility and risk, SLDB or JMAC?

Does the media refer more to SLDB or JMAC?

Is SLDB or JMAC more profitable?

Do insiders & institutionals hold more shares of SLDB or JMAC?

Which has preferable valuation and earnings, SLDB or JMAC?

Summary

How does Maxpro Capital Acquisition compare to Allogene Therapeutics?

Does the media refer more to ALLO or JMAC?

Which has more volatility and risk, ALLO or JMAC?

Is ALLO or JMAC more profitable?

Do analysts rate ALLO or JMAC?

Which has preferable valuation & earnings, ALLO or JMAC?

Do insiders and institutionals believe in ALLO or JMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools